Eva S. Laube

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

J. Wills, G. Soff, G. Brar, 2016, Journal of Thrombosis and Thrombolysis.

Long-term risk of adverse outcomes according to atrial fibrillation type

F. Eberli, D. Conen, K. Lovblad, 2022, Scientific Reports.

Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.

J. Wills, Dipti Gupta, G. Soff, 2016, The American journal of cardiology.

Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis.

L. Räber, O. Hess, P. Wenaweser, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban

J. Wills, G. Soff, S. Mantha, 2016, American journal of hematology.

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban

Lauren E. Molloy, J. Wills, G. Soff, 2016, American journal of hematology.